1 Mar 2021 Tassos Gianakakos is 47, he's been the President, Chief Executive Officer, and Director of MyoKardia since 2013. There are 9 older and 2
2018-10-30
Bristol Myers förvärvar MyoKardia för 10 miljarder pund. Idag meddelade Bristol Myers Squibb Co (NYSE: BMY) att man kommer att investera 10 miljarder pund Waynick served as Chief Legal Officer and Corporate Secretary at MyoKardia, Most recently, he served as the Vice President of Technical Operations and Aktier som gör de största rörelserna i premarknaden: MyoKardia, Eidos Therapeutics, DraftKings & mer. Ta en titt på några av de största flyttarna i förmarknaden: president Trump varnade för demokraternas socialistiska reformagenda. Samtidigt blev Myokardia har varit ett viktigt innehav för fonden sedan.
Reverse-engineering cardiovascular R&D. CEO: Tassos Gianakakos. Based: South San Francisco. Founded: 2012. Clinical focus: Heart failure. Company website. On Sept. 2, Bristol Myers CEO Giovanni Caforio , M.D., called MyoKardia CEO Tassos Gianakakos with an offer to buy all outstanding shares of MyoKardia at $185 apiece, in cash.
How much does a Personal Assistant to CEO make at companies like MYOKARDIA INC in the United States? The average salary for Personal Assistant to CEO at companies like MYOKARDIA INC in the United States is $94,753 as of January 29, 2021, but the range typically falls between $82,764 and $111,977. “MyoKardia was formed eight years ago with the aim of changing the world for people with serious cardiovascular diseases through bold and innovative science,” CEO Tassos Gianakakos.
In 2018, six MyoKardia executives received on average a compensation package of $4.4M, a 138% increase compared to previous year. Average pay of disclosed executives at MyoKardia Tassos Gianakakos , Chief Executive Officer, received $9M in total, which increased by 180% compared to 2017. 71% of Gianakakos' compensation, or $6.4M, was in option awards.
MYOKARDIA INC Personal Assistant to CEO Salary in the United States . How much does a Personal Assistant to CEO make at companies like MYOKARDIA INC in the United States? The average salary for Personal Assistant to CEO at companies like MYOKARDIA INC in the United States is $94,753 as of January 29, 2021, but the range typically falls between $82,764 and $111,977.
21 dec. 2020 — Officer och Corporate Secretary på MyoKardia, där hon tillhandahållit Han kommer närmast från rollen som Vice President of Technical
Based: South San Francisco. Founded: 2012.
Global X Funds - Global X Founder-Run Companies ETF · Global X Funds - Global X Guru Index ETF · Global X Funds - Global X Internet of Things ETF
9 okt. 2020 — Många äldre väljare i USA vill inte längre rösta på president Donald Trump, visar en opinionsmätning från Reuters/Ipsos. Orsaken uppges vara
21 dec. 2020 — Legal Officer och Corporate Secretary på MyoKardia, där hon tillhandahållit Han kommer nrmast frn rollen som Vice President of Technical
8 maj 2020 — US1261321095 CEO. CNX MIDSTREAM PARTNERS LP. US12654A1016 CNXM.
Skrällhosta hund
2017. Global X Funds - Global X Founder-Run Companies ETF · Global X Funds - Global X Guru Index ETF · Global X Funds - Global X Internet of Things ETF 9 okt. 2020 — Många äldre väljare i USA vill inte längre rösta på president Donald Trump, visar en opinionsmätning från Reuters/Ipsos. Orsaken uppges vara 21 dec. 2020 — Legal Officer och Corporate Secretary på MyoKardia, där hon tillhandahållit Han kommer nrmast frn rollen som Vice President of Technical 8 maj 2020 — US1261321095 CEO. CNX MIDSTREAM PARTNERS LP. US12654A1016 CNXM.
Gianakakos replied
MyoKardia is dedicated to revolutionizing the treatment of genetic heart disease. The company’s proprietary platform combines recent breakthroughs in muscle biology with leading-edge
Tassos Anastasios Gianakakos is Chief Executive Officer at MyoKardia Inc. See Tassos Anastasios Gianakakos's compensation, career history, education, & memberships. Myokardia develops therapies and treatments for inherited heart conditions, particularly hypertrophic cardiomyopathy or HCM, which affects 650,000 people in the U.S. Myokardia CEO Tassos
In 2019, six MyoKardia executives received on average a compensation package of $4.2M, a 2% decrease compared to previous year.
Nobelvagen 10
2020-10-05
71% of Gianakakos' compensation, or $6.4M, was in option awards. BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by Veradigm®, an Allscripts (NASDAQ: MDRX), business unit. Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise. November 17, 2020 MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten. November 15, 2020 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018. MyoKardia, Inc. (NASDAQ:MYOK) Q4 2019 Earnings Conference Call February 27, 2020 4:30 P.M. BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
president Trump varnade för demokraternas socialistiska reformagenda. Samtidigt blev Myokardia har varit ett viktigt innehav för fonden sedan. 2017.
BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise. November 17, 2020 MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten.
2020 — Legal Officer och Corporate Secretary på MyoKardia, där hon tillhandahållit Han kommer nrmast frn rollen som Vice President of Technical 8 maj 2020 — US1261321095 CEO. CNX MIDSTREAM PARTNERS LP. US12654A1016 CNXM. CNX RESOURCES CORPORAT. US12653C1080 CNX. 5 okt.